4 Treatment Options for Spinal Muscular Atrophy
Targeted Therapies
Two targeted therapies are approved by the US Food and Drug Administration to treat the underlying causes of spinal muscular atrophy. These include nusinersen for adults and children as well as onasemnogene abeparvovec-xioi for babies under two years old. Many clinical studies have shown that these treatments can have significant effects on the condition by slowing or limiting its progression. However, they are quite new approaches, so more research is still needed to confirm long-term effects. [5]
